Literature DB >> 24436048

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Marie Will1, Alice Can Ran Qin, Weiyi Toy, Zhan Yao, Vanessa Rodrik-Outmezguine, Claudia Schneider, Xiaodong Huang, Prashant Monian, Xuejun Jiang, Elisa de Stanchina, José Baselga, Ningshu Liu, Sarat Chandarlapaty, Neal Rosen.   

Abstract

The effects of selective phosphoinositide 3-kinase (PI3K) and AKT inhibitors were compared in human tumor cell lines in which the pathway is dysregulated. Both caused inhibition of AKT, relief of feedback inhibition of receptor tyrosine kinases, and growth arrest. However, only the PI3K inhibitors caused rapid induction of cell death. In seeking a mechanism for this phenomenon, we found that PI3K inhibition, but not AKT inhibition, causes rapid inhibition of wild-type RAS and of RAF-MEK-ERK signaling. Inhibition of RAS-ERK signaling is transient, rebounding a few hours after drug addition, and is required for rapid induction of apoptosis. Combined MEK and AKT inhibition also promotes cell death, and in murine models of HER2(+) cancer, either pulsatile PI3K inhibition or combined MEK and AKT inhibition causes tumor regression. We conclude that PI3K is upstream of RAS and AKT and that pulsatile inhibition of both pathways is sufficient for effective antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24436048      PMCID: PMC4049524          DOI: 10.1158/2159-8290.CD-13-0611

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  31 in total

1.  A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.

Authors:  A Yart; M Laffargue; P Mayeux; S Chretien; C Peres; N Tonks; S Roche; B Payrastre; H Chap; P Raynal
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

Authors:  Shiann-Tarng Jou; Nick Carpino; Yutaka Takahashi; Roland Piekorz; Jyh-Rong Chao; Neena Carpino; Demin Wang; James N Ihle
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

5.  Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence on signal strength.

Authors:  B C Duckworth; L C Cantley
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

6.  BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.

Authors:  Ningshu Liu; Bruce R Rowley; Cathy O Bull; Claudia Schneider; Andrea Haegebarth; Christoph A Schatz; Paul R Fracasso; Dean P Wilkie; Martin Hentemann; Scott M Wilhelm; William J Scott; Dominik Mumberg; Karl Ziegelbauer
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

7.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.

Authors:  Adrian Britschgi; Rita Andraos; Heike Brinkhaus; Ina Klebba; Vincent Romanet; Urs Müller; Masato Murakami; Thomas Radimerski; Mohamed Bentires-Alj
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 8.  The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Authors:  Josh Lauring; Ben Ho Park; Antonio C Wolff
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

Review 9.  Development of PI3K inhibitors: lessons learned from early clinical trials.

Authors:  Jordi Rodon; Rodrigo Dienstmann; Violeta Serra; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2013-02-12       Impact factor: 66.675

10.  A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation.

Authors:  Elizabeth Clayton; Giuseppe Bardi; Sarah E Bell; David Chantry; C Peter Downes; Alexander Gray; Lisa A Humphries; David Rawlings; Helen Reynolds; Elena Vigorito; Martin Turner
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  90 in total

Review 1.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

Review 2.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Authors:  Andrew J Armstrong; Susan Halabi; Patrick Healy; Joshi J Alumkal; Carolyn Winters; Julie Kephart; Rhonda L Bitting; Carey Hobbs; Colleen F Soleau; Tomasz M Beer; Rachel Slottke; Kelly Mundy; Evan Y Yu; Daniel J George
Journal:  Eur J Cancer       Date:  2017-05-11       Impact factor: 9.162

4.  Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.

Authors:  Saya H Ebbesen; Maurizio Scaltriti; Carl U Bialucha; Natasha Morse; Edward R Kastenhuber; Hannah Y Wen; Lukas E Dow; José Baselga; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

5.  AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.

Authors:  Xiaoyu Chen; Danrui Cui; Yanli Bi; Jianfeng Shu; Xiufang Xiong; Yongchao Zhao
Journal:  Cell Cycle       Date:  2018-09-19       Impact factor: 4.534

6.  Anticancer drugs: a clearer pathway view.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

7.  Signalling: a clearer pathway view.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2014-02-06       Impact factor: 60.716

8.  The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Mol Cell Oncol       Date:  2015-04-30

9.  Protective Effects of Fisetin Against 6-OHDA-Induced Apoptosis by Activation of PI3K-Akt Signaling in Human Neuroblastoma SH-SY5Y Cells.

Authors:  Ryoko Watanabe; Takumi Kurose; Yuta Morishige; Ko Fujimori
Journal:  Neurochem Res       Date:  2017-12-04       Impact factor: 3.996

10.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Authors:  Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2018-08-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.